CSIMarket
 
Ani Pharmaceuticals Inc  (ANIP)
Other Ticker:  
 
 
Price: $65.4800 $0.90 1.394%
Day's High: $65.78 Week Perf: -1.24 %
Day's Low: $ 64.20 30 Day Perf: -3.16 %
Volume (M): 207 52 Wk High: $ 70.81
Volume (M$): $ 13,567 52 Wk Avg: $55.88
Open: $64.20 52 Wk Low: $36.99



 Market Capitalization (Millions $) 1,321
 Shares Outstanding (Millions) 20
 Employees 685
 Revenues (TTM) (Millions $) 487
 Net Income (TTM) (Millions $) 19
 Cash Flow (TTM) (Millions $) 168
 Capital Exp. (TTM) (Millions $) 19

Ani Pharmaceuticals Inc
Ani Pharmaceuticals Inc. is an innovative specialty pharmaceutical company that focuses on the development, manufacturing, and commercialization of high-quality generic and branded prescription pharmaceuticals. The company was founded in 2002 and is headquartered in Baudette, Minnesota, United States.

Ani Pharmaceuticals operates in four main segments: Generic Pharmaceuticals, Branded Pharmaceuticals, Contract Manufacturing, and Specialty Pharmaceuticals. The Generic Pharmaceuticals segment develops and markets generic products that are equivalent to their brand-name equivalents but are lower-priced alternatives. The Branded Pharmaceuticals segment focuses on branded products that are marketed to specific niche markets, usually where there are no generic alternatives. The Contract Manufacturing segment provides contract manufacturing services to other pharmaceutical companies, utilizing the company's expertise in formulation development, analytical testing, and commercial-scale manufacturing. The Specialty Pharmaceuticals segment develops and markets specialty products that typically have lower competition, smaller markets, and higher margins than generic or branded products.

Ani Pharmaceuticals has a portfolio of over 100 generic and branded products covering several therapeutic categories, including oncology, cardiology, dermatology, pain management, and more. It markets its products through wholesalers, distributors, retailers, and other customers in the United States, Canada, and other international markets.

Apart from its product portfolio, Ani Pharmaceuticals has a state-of-the-art FDA-approved manufacturing facility that can produce several dosage forms such as tablets, capsules, creams, gels, and liquids. The company has a highly experienced team of scientists, researchers, and technicians who work relentlessly to develop new and innovative products that meet the evolving needs of the healthcare industry.

Ani Pharmaceuticals is committed to achieving high levels of growth through organic growth and strategic partnerships and acquisitions. The company has made several strategic acquisitions over the years to expand its product pipeline and enhance its manufacturing capabilities. It also partners with other pharmaceutical companies to develop and commercialize joint products.

In summary, Ani Pharmaceuticals Inc. is a leading specialty pharmaceutical company with a strong focus on the development, manufacturing, and commercialization of high-quality generic and branded prescription pharmaceuticals. The company has a diversified product portfolio, state-of-the-art manufacturing facility, and a highly experienced team of experts. It is committed to innovation, growth, and exceeding the expectations of its customers, employees, and shareholders.


   Company Address: 210 Main Street West Baudette 56623 MN
   Company Phone Number: 634-3500   Stock Exchange / Ticker: NASDAQ ANIP
   ANIP is expected to report next financial results on May 10, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

ANI Pharmaceuticals Bolsters Access to Medications with Baclofen Oral Suspension, Boosting Revenue Growth

Published Tue, Apr 9 2024 10:50 AM UTC

The launch of Baclofen Oral Suspension marks a momentous milestone for ANI Pharmaceuticals. This generic version of Fleqsuvy offers patients an affordable yet equally effective treatment option for muscle spasms and multiple sclerosis. By providing access to Baclofen Oral Suspension, ANI Pharmaceuticals is contributing to improved patient outcomes and accessibility to necess...

Product Service News

ANI Pharmaceuticals Introduces Cost-effective Generic Version of Levaquin: Levofloxacin Oral Solution

Published Wed, Mar 27 2024 10:50 AM UTC

Sophisticated ANI Pharmaceuticals, a leading pharmaceutical company, has recently made a significant announcement regarding the launch of Levofloxacin Oral Solution, a generic version of the widely-used Reference Listed Drug (RLD), Levaquin. This development marks a significant milestone in the pharmaceutical industry, providing healthcare professionals and patients alike wi...

Ani Pharmaceuticals Inc

2. Embracing Success: ANI Pharmaceuticals Inc's Remarkable Turnaround in Q4 2023

As a pharmaceutical industry enthusiast and an avid follower of ANI Pharmaceuticals Inc, I am thrilled to report on the recent financial results and business highlights of this major pharmaceutical preparations company. The October to December 31, 2023 fiscal time-frame has proven to be a turning point for ANI Pharmaceuticals Inc, as they have witnessed significant improvements in their earnings and revenue.
Starting with earnings per share, ANI Pharmaceuticals Inc saw a substantial positive shift from $-0.23 a year prior to $0.03 per share in the recent fiscal time-frame. This impressive improvement showcases the company's ability to effectively manage their financial performance and generate profits. Additionally, ANI Pharmaceuticals Inc reported earnings per share of $0.85 compared to $-3.05 in the previous fiscal year, indicating remarkable growth.

Product Service News

ANI Pharmaceuticals Leads the Way with the of Pentoxifylline Extended-Release Tablets, USP, amidst Impressive Revenue Growth

Published Tue, Jan 23 2024 11:50 AM UTC

ANI Pharmaceuticals, a leading pharmaceutical company, has made yet another groundbreaking achievement with the successful launch of Pentoxifylline Extended-Release (ER) Tablets, USP 400mg. This remarkable development not only brings a new medication option to patients but also showcases the company's commitment to innovation and expansion in the pharmaceutical industry.Pent...

Ani Pharmaceuticals Inc

Ani Pharmaceuticals Inc Roars with Positive Income: A Stellar Financial Performance Ending September 30, 2023



In the latest financial quarter, Ani Pharmaceuticals Inc (ANIP) showcased its exceptional growth potential by reporting positive income, surging revenues, and improving profit margins. The company's financial results have far exceeded expectations, positioning ANIP as a notable player in the Major Pharmaceutical Preparations sector. Furthermore, the market has responded positively, with ANIP's stock experiencing a solid gain of 8.15% in the last 5 trading days and reaching its 52-week high.
Positive Growth Signals:
ANIP's impressive financial interval ending September 30, 2023, reflected substantial improvement compared to the previous year. The company's income turned positive, demonstrating a significant leap from $-0.55 to $0.45 per share. Moreover, on a quarter-on-quarter basis, income per share soared by an astonishing 55.17%, from $0.29 per share to $0.45 per share.






 

Ani Pharmaceuticals Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com